Medicus Pharma appoints Andrew Smith as chief operating officer

PHILADELPHIA - Medicus Pharma Ltd. (NASDAQ:MDCX), a clinical-stage pharmaceutical company with a market capitalization of $39.42 million, has appointed Andrew Smith as chief operating officer, the company announced Monday in a press release. The appointment comes as the company’s stock has declined 24.55% over the past year, according to InvestingPro data.

Smith brings over three decades of experience to the role, most recently serving as Chief Executive of SR Asset Management until its sale in 2024. Previously, he held various leadership positions at Aberdeen Asset Management Inc., including Co-Head of Americas and Chief Operating Officer.

"We are delighted to welcome Andrew to the leadership team," said Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma.

The company also provided an update on its SKNJCT-003 Phase 2 clinical study, which is evaluating the use of doxorubicin-containing microneedle arrays (D-MNA) for the non-invasive treatment of basal cell carcinoma. Analysts maintain a strong buy consensus on the stock, with price targets ranging from $5.61 to $27, significantly above the current trading price of $2.49. More than 50 of the planned 90 patients have been randomized across nine clinical sites in the United States since the study began in August 2024.

In March 2025, Medicus reported a preliminary interim analysis showing more than 60% clinical clearance after randomizing over 50% of the initially targeted 60 patients. The company noted that these interim findings may not correlate with final study results.

The investigational review board increased the study’s target enrollment from 60 to 90 subjects in April 2025, and Medicus has expanded clinical trial sites to Europe.

Additionally, the company is conducting the SKNJCT-004 clinical study in the United Arab Emirates, which aims to randomize 36 patients across four sites.

In April 2025, Medicus announced entering a binding letter of intent to acquire Antev Ltd., a UK-based biotech company developing Teverelix, a GnRH antagonist for prostate cancer patients.

In other recent news, Medicus Pharma Ltd. has completed a $7 million public offering, with the proceeds primarily intended for advancing clinical trials, including a Phase 2 trial for basal cell carcinoma treatment. The company has expanded its Phase 2 clinical trial for this non-invasive treatment, increasing patient enrollment from sixty to ninety participants across the United States and Europe. Additionally, Medicus Pharma has announced its intention to acquire Antev Ltd., a UK-based biotech firm, in a transaction that could include contingent payments tied to FDA approvals. This acquisition is expected to bring Antev’s drug candidate, Teverelix, into Medicus Pharma’s portfolio, a treatment with significant market potential for prostate cancer and acute urinary retention. In light of this acquisition, Boral Capital has raised Medicus Pharma’s stock target from $14.00 to $27.00 while maintaining a Buy rating. The company is also advancing a novel treatment for equine squamous cell carcinoma, having submitted a product development plan under the FDA’s Investigational New Animal Drug designation. This plan includes a study to assess the efficacy of a microneedle patch delivering doxorubicin directly to tumors. Medicus Pharma is actively conducting a Phase 2 clinical study for a similar human treatment, with positive interim results reported.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.